35,621 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by LPL Financial LLC

LPL Financial LLC purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,621 shares of the company's stock, valued at approximately $2,738,000. LPL Financial LLC owned approximately 0.13% of GeneDx as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. MCF Advisors LLC increased its stake in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after buying an additional 182 shares during the period. Global Retirement Partners LLC bought a new stake in GeneDx during the fourth quarter worth approximately $28,000. KLP Kapitalforvaltning AS acquired a new stake in GeneDx in the fourth quarter worth approximately $200,000. Evolution Wealth Advisors LLC acquired a new position in shares of GeneDx during the 4th quarter valued at $202,000. Finally, Victory Capital Management Inc. bought a new stake in shares of GeneDx in the 4th quarter worth $209,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of research analyst reports. The Goldman Sachs Group lifted their target price on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. TD Cowen increased their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, GeneDx presently has a consensus rating of "Moderate Buy" and an average price target of $72.33.

Remove Ads

GeneDx Trading Down 2.0 %

Shares of WGS traded down $2.07 during midday trading on Wednesday, hitting $100.15. The stock had a trading volume of 421,293 shares, compared to its average volume of 675,268. The business has a 50-day simple moving average of $91.91 and a two-hundred day simple moving average of $78.94. The firm has a market cap of $2.81 billion, a P/E ratio of -51.10 and a beta of 1.93. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a fifty-two week low of $8.63 and a fifty-two week high of $115.60.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. As a group, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84. Following the completion of the sale, the chief financial officer now directly owns 5,446 shares of the company's stock, valued at $515,845.12. This trade represents a 14.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Katherine Stueland sold 2,731 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $94.73, for a total value of $258,707.63. Following the completion of the sale, the chief executive officer now directly owns 7,752 shares of the company's stock, valued at approximately $734,346.96. The trade was a 26.05 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 138,780 shares of company stock worth $12,907,437. 27.30% of the stock is currently owned by company insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.